Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst Julian Harrison maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $13 to $15.
HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.
FDA lifts clinical hold on Rezolute's RZ358 for treating congenital hyperinsulinism, allowing U.S. participants in Phase 3 ...
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Rezolute (NASDAQ:RZLT) with a Buy rating and announces Price T...
Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $8 to $10.
HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.
Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company committed to...
BTIG analyst Julian Harrison initiates coverage on Rezolute (NASDAQ:RZLT) with a Buy rating and announces Price Target of $13.
